- Home
- ACN vs AZN Comparison
ACN vs AZN Comparison
Compare ACN & AZN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ACN
- AZN
- Stock Information
- Founded
- ACN 1989
- AZN 1992
- Country
- ACN Ireland
- AZN United Kingdom
- Employees
- ACN N/A
- AZN N/A
- Industry
- ACN Business Services
- AZN Biotechnology: Pharmaceutical Preparations
- Sector
- ACN Consumer Discretionary
- AZN Health Care
- Exchange
- ACN Nasdaq
- AZN Nasdaq
- Market Cap
- ACN 174.8B
- AZN 205.5B
- IPO Year
- ACN N/A
- AZN 1993
- Fundamental
- Price
- ACN $307.97
- AZN $67.57
- Analyst Decision
- ACN Buy
- AZN Strong Buy
- Analyst Count
- ACN 19
- AZN 5
- Target Price
- ACN $377.89
- AZN $92.33
- AVG Volume (30 Days)
- ACN 2.9M
- AZN 5.3M
- Earning Date
- ACN 06-20-2025
- AZN 04-29-2025
- Dividend Yield
- ACN 1.92%
- AZN 2.28%
- EPS Growth
- ACN 9.77
- AZN 22.71
- EPS
- ACN 12.12
- AZN 4.97
- Revenue
- ACN $67,221,493,000.00
- AZN $54,982,000,000.00
- Revenue This Year
- ACN $6.82
- AZN $9.27
- Revenue Next Year
- ACN $5.67
- AZN $6.02
- P/E Ratio
- ACN $25.41
- AZN $27.17
- Revenue Growth
- ACN 4.10
- AZN 15.48
- 52 Week Low
- ACN $275.01
- AZN $61.24
- 52 Week High
- ACN $398.35
- AZN $87.68
- Technical
- Relative Strength Index (RSI)
- ACN 56.42
- AZN 41.25
- Support Level
- ACN $303.20
- AZN $67.26
- Resistance Level
- ACN $313.25
- AZN $72.69
- Average True Range (ATR)
- ACN 5.53
- AZN 1.30
- MACD
- ACN 3.28
- AZN -0.03
- Stochastic Oscillator
- ACN 84.03
- AZN 12.03
About ACN Accenture plc (Ireland)
Accenture is a leading global IT services firm that provides consulting, strategy, and technology and operational services. These services run the gamut from aiding enterprises with digital transformation to procurement services to software system integration. The company provides its IT offerings to a variety of sectors, including communications, media and technology, financial services, health and public services, consumer products, and resources. Accenture employs just under 500,000 people throughout 200 cities in 51 countries.
About AZN AstraZeneca PLC
A merger between Astra of Sweden and Zeneca Group of the United Kingdom formed AstraZeneca in 1999. The firm sells branded drugs across a number of major therapeutic areas, including oncology (about 40% of total revenue), cardiovascular, renal, and metabolic (25%), rare disease (17%), and respiratory and immunology (15%). The majority of sales comes from international markets, with the United States representing close to one third of its sales.